PMID- 11893034
OWN - NLM
STAT- MEDLINE
DCOM- 20020822
LR  - 20220311
IS  - 1541-2016 (Print)
IS  - 1533-4058 (Linking)
VI  - 10
IP  - 1
DP  - 2002 Mar
TI  - Comparison of HER-2/neu oncogene amplification detected by fluorescence in situ 
      hybridization in lobular and ductal breast cancer.
PG  - 40-6
AB  - BACKGROUND: Abnormal expression of the HER-2/neu oncogene, a tyrosine kinase-type 
      transmembrane growth factor receptor localized to chromosome 17q, has been 
      associated with poor prognosis and the prediction of therapy response in invasive 
      breast cancer. The comparative incidence and significance of HER-2/neu gene 
      amplification for lobular and ductal breast cancer have not been previously 
      characterized. DESIGN: Formalin-fixed, paraffin-embedded primary breast cancer 
      tissue sections from 71 women diagnosed with invasive lobular carcinoma were 
      tested for HER-2/neu gene amplification by fluorescence in situ hybridization 
      (FISH) method using the Ventana unique sequence probe (Ventana Medical Systems, 
      Tucson, AZ). A series of 106 cases of invasive ductal carcinoma was similarly 
      processed and tested. Lymph node status was available for 155 (88%) of the 177 
      cases and 82 (46%) were lymph node-negative (LN-) and 73 (41%) were lymph 
      node-positive (LN+). Patients were treated for a mean of 65 months (range 1-169 
      months). RESULTS: 9 of 71 (13%) cases of lobular cancer featured HER-2/neu gene 
      amplification, whereas 51 (48%) of 106 cases of ductal cancer showed 
      amplification (P < 0.0001). On univariate analysis of combined lobular and ductal 
      cases, HER-2/neu gene amplification detected by FISH predicted disease-related 
      death (P < 0.0001). HER-2/neu gene amplification also predicted disease-related 
      death in lobular cases alone (P = 0.003), LN+ lobular cases separately (P = 
      0.019), and LN- and LN+ ductal cases separately and alone (P < 0.0001). 
      Multivariate analysis of the lobular group alone revealed that LN+ status (P = 
      0.015) and stage (P = 0.01) were independent predictors of disease-related death, 
      and HER-2/neu gene amplification reached near significance (P = 0.086). In the 
      ductal carcinoma group alone, HER-2/neu gene amplification (P = 0.03), lymph node 
      status (P = 0.0001), tumor stage (P = 0.0001), and tumor grade (P = 0.044) were 
      independent predictors of overall disease survival. CONCLUSIONS: HER-2/neu gene 
      amplification detected by FISH was identified at a significantly lower rate in 
      lobular compared with ductal breast cancer. HER-2/neu gene amplification when 
      present in lobular breast cancer is a significant adverse prognostic factor.
FAU - Rosenthal, Seth I
AU  - Rosenthal SI
AD  - Department of Pathology and Laboratory Medicine, Albany Medical Center, New York, 
      USA.
FAU - Depowski, Peter L
AU  - Depowski PL
FAU - Sheehan, Christine E
AU  - Sheehan CE
FAU - Ross, Jeffrey S
AU  - Ross JS
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Appl Immunohistochem Mol Morphol
JT  - Applied immunohistochemistry & molecular morphology : AIMM
JID - 100888796
SB  - IM
MH  - Breast Neoplasms/*genetics/pathology
MH  - Carcinoma, Ductal, Breast/*genetics/pathology
MH  - Carcinoma, Lobular/*genetics/pathology
MH  - Female
MH  - *Gene Amplification
MH  - *Genes, erbB-2
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - *Oncogenes
EDAT- 2002/03/15 10:00
MHDA- 2002/08/23 10:01
CRDT- 2002/03/15 10:00
PHST- 2002/03/15 10:00 [pubmed]
PHST- 2002/08/23 10:01 [medline]
PHST- 2002/03/15 10:00 [entrez]
AID - 10.1097/00129039-200203000-00007 [doi]
PST - ppublish
SO  - Appl Immunohistochem Mol Morphol. 2002 Mar;10(1):40-6. doi: 
      10.1097/00129039-200203000-00007.